Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 706 to 720 of 1108 results for infections

  1. The NxStage System One NX1000‑1 home haemodialysis device for renal replacement therapy in chronic kidney disease (MIB12)

    NICE has developed a medtech innovation briefing (MIB) on The NxStage System One NX1000-1 home haemodialysis device for renal replacement therapy in chronic kidney disease .

  2. Glecaprevir–pibrentasvir for treating chronic hepatitis C (TA499)

    Evidence-based recommendations on glecaprevir–pibrentasvir (Maviret) for treating chronic hepatitis C in adults.

  3. Methadone and buprenorphine for the management of opioid dependence (TA114)

    Evidence-based recommendations on methadone and buprenorphine (oral formulations) for managing opioid dependence in adults.

  4. Neonatal parenteral nutrition (QS205)

    This quality standard covers parenteral nutrition (intravenous feeding) for babies born preterm, up to 28 days after their due birth date, and babies born at term, up to 28 days after their birth. It describes high-quality care in priority areas for improvement.

  5. How cost effective are cohort testing programmes: - as a stand-alone programme, or - as an extension of the NHS Health Check programme?

    Comes from guidance Hepatitis B and C testing: people at risk of infection Number PH43 Date issued December 2012 Other

  6. What cost-effective interventions ensure continuity of care for prisoners who are diagnosed with chronic hepatitis B or C in prison?

    Comes from guidance Hepatitis B and C testing: people at risk of infection Number PH43 Date issued December 2012 Other

  7. How many children in the UK are infected with chronic hepatitis B and C and which subgroups of the population do they come from?

    Comes from guidance Hepatitis B and C testing: people at risk of infection Number PH43 Date issued December 2012 Other

  8. How many people in the UK are infected with chronic hepatitis B and C and which subgroups of the population do they come from?

    Comes from guidance Hepatitis B and C testing: people at risk of infection Number PH43 Date issued December 2012 Other

  9. What cost-effective interventions can be used to increase hepatitis B case-finding among migrant populations in primary and secondary care?

    Comes from guidance Hepatitis B and C testing: people at risk of infection Number PH43 Date issued December 2012 Other

  10. How cost effective are alternative testing sites, such as community pharmacist programmes, for increasing the number of people who are tested and treated for hepatitis B and C?

    Comes from guidance Hepatitis B and C testing: people at risk of infection Number PH43 Date issued December 2012 Other

  11. What impact does increased knowledge and awareness of hepatitis B and C among the general public have on the uptake of testing and treatment?

    Comes from guidance Hepatitis B and C testing: people at risk of infection Number PH43 Date issued December 2012 Other

  12. Percutaneous intradiscal radiofrequency treatment of the intervertebral disc nucleus for low back pain (HTG399)

    Evidence-based recommendations on percutaneous intradiscal radiofrequency treatment of the intervertebral disc nucleus for low back pain. This involves relieving low back pain by delivering heat energy to the damaged disc.

  13. How can the uptake of hepatitis C treatment be improved? What factors influence whether or not specific groups at increased risk will begin and complete hepatitis C treatment?

    Comes from guidance Hepatitis B and C testing: people at risk of infection Number PH43 Date issued December 2012 Other

  14. Research should report:

    including: bleeding symptomatic and asymptomatic intracranial bleeding infection cannulation complications pain. Source guidance details

  15. Artificial intelligence (AI)-assisted echocardiography analysis and reporting to support the diagnosis and monitoring of heart failure: early-use assessment (HTG779)

    Evidence-based recommendations on the early use of artificial intelligence (AI)-assisted echocardiography analysis and reporting to support the diagnosis and monitoring of heart failure.